Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
As the United States shifts away from fossil-fuel-burning cars and trucks, scientists at the Department of Energy’s Oak Ridge and Argonne national laboratories are exploring options for another form of transportation: trains. The research focuses on zero-carbon hydrogen and other low-carbon fuels as viable alternatives to diesel for the rail industry.
Researchers at the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2022 R&D 100 Awards, plus special recognition for a battery-related green technology product.
ORNL researchers have developed an upcycling approach that adds value to discarded plastics for reuse in additive manufacturing, or 3D printing.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
A team of scientists from LanzaTech, Northwestern University and ORNL have developed carbon capture technology that harnesses emissions from industrial processes to produce acetone and isopropanol
A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.
Nearly a billion acres of land in the United States is dedicated to agriculture, producing more than a trillion dollars of food products to feed the country and the world. Those same agricultural processes, however, also produced an estimated 700 million metric tons of carbon dioxide equivalent in 2018, according to the U.S. Department of Agriculture.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.